Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dornase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis
Details : Undisclosed
Product Name : Tigerase
Product Type : Enzyme
Upfront Cash : Inapplicable
July 13, 2020
Lead Product(s) : Dornase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dornase Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 07, 2020
Lead Product(s) : Dornase Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dornase Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation
Deal Size : Inapplicable
Deal Type : Inapplicable
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
June 01, 2020
Lead Product(s) : Dornase Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Hamilton Health Sciences | F. Hoffmann-La Roche | Exactis Innovation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dornase Alfa
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Genentech | National Eye Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 08, 2016
Lead Product(s) : Dornase Alfa
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Genentech | National Eye Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dornase Alfa
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
October 23, 2012
Lead Product(s) : Dornase Alfa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dornase Alfa
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
May 19, 2011
Lead Product(s) : Dornase Alfa
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dornase Alfa
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable
Pulmozyme in Cystic Fibrosis With Sinusitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 02, 2010
Lead Product(s) : Dornase Alfa
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Genentech
Deal Size : Inapplicable
Deal Type : Inapplicable